Streetbeat News

AEON

AEON Biopharma, Inc.

http://www.aeonbiopharma.com

Industry

Biotechnology

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Open

0.61

Mkt cap

24M

Volume

130K

High

0.66

P/E Ratio

-4.75

52-wk high

17.17

Low

0.60

Div yield

N/A

52-wk low

0.60

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on AEON Biopharma and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 11:26 am

AEON Biopharma shares are trading higher following the company's announcement of a resource prioritization and cost reduction plan.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 2:53 pm

AEON Biopharma, Inc. (NYSE:AEON) announced a strategic reprioritization and cost reduction plan, including a 55% workforce reduction, to extend its cash runway into Q4 2024. The company is evaluating financing options for its late-stage clinical pipeline for ABP-450.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 12:17 pm

The article highlights the pre-market movements of various health care stocks on Thursday. Notable gainers include OneMedNet (ONMD), iSpecimen (ISPC), P3 Health Partners (PIII), Bicycle Therapeutics (BCYC), Calliditas Therapeutics (CALT), and AEON Biopharma (AEON). On the losing side, Ensysce Biosciences (ENSC), Cytokinetics (CYTK), DermTech (DMTK), SILO Pharma (SILO), Tango Therapeutics (TNGX), and Vicarious Surgical (RBOT) saw declines.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 12:06 pm

HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but has significantly lowered the price target from $18 to $6.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 6:04 pm

AEON Biopharma reported a Q1 2024 adjusted EPS loss of $(3.17), significantly missing the analyst consensus estimate of $(0.31) by 922.58%.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:29 pm

HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on AEON Biopharma (AMEX:AEON) with an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:44 am

U.S. stocks saw significant gains with the S&P 500 rising over 1%, led by a strong performance in the information technology sector. Hershey Company reported better-than-expected earnings, boosting its stock. Meanwhile, Safe & Green Holdings, Upland Software, and Tandem Diabetes Care saw substantial increases in their share prices following positive financial results. Conversely, AEON Biopharma, Sprout Social, and Owens & Minor experienced sharp declines due to disappointing financial outcomes or trial results.

Portfolio Pulse from Avi Kapoor

May 03, 2024 | 6:30 pm

Nasdaq surged 2% with Apple posting upbeat Q2 results, announcing a $110-billion stock buyback and a dividend increase. Information technology shares led gains, while energy shares fell. Safe & Green Holdings, Upland Software, and Tandem Diabetes Care saw significant stock increases after positive financial results. Conversely, AEON Biopharma, Sprout Social, and Owens & Minor experienced substantial declines following disappointing outcomes.

Portfolio Pulse from Avi Kapoor

May 03, 2024 | 4:49 pm

Healthcare stocks experienced significant movements in Friday's intraday session, with notable gainers including Eliem Therapeutics, Ardelyx, Twist Bioscience, Tandem Diabetes Care, Alignment Healthcare, and Syra Health, primarily due to recent earnings reports. Conversely, Mobile-health Network, AEON Biopharma, CG Oncology, Owens & Minor, Allarity Therapeutics, and Nuwellis faced declines.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.